References of "Legrand, Delphine"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailNGAL biomarqueur de lésion rénale
Gagneux-Brunon, Amandine; DELANAYE, Pierre ULg; LEGRAND, Delphine ULg et al

in Néphrologie & Thérapeutique (2012), 8(7), 508-515

Le diagnostic precoce de l’insufissance renale aigue (IRA) est necessaire et devrait se faire au stade de lesion renale avant meme la degradation du debit de filtration glomerulaire. Plusieurs ... [more ▼]

Le diagnostic precoce de l’insufissance renale aigue (IRA) est necessaire et devrait se faire au stade de lesion renale avant meme la degradation du debit de filtration glomerulaire. Plusieurs biomarqueurs d’atteinte renale aigue sont actuellement a l’etude. Parmi ceux-ci, le Neutrophil Gelatinase Associated Lipocalin (NGAL) semble l’un des plus prometteurs et fait l’objet de nombreuses publications. La performance diagnostique de NGAL, dose dans le plasma ou les urines, pour le depistage de l’IRA depend de nombreux facteurs. Bien que les donnees experimentales recentes soient en faveur de l’utilisation preferentielle du dosage urinaire de NGAL, les donnees cliniques issues de nombreuses etudes ne permettent pas de trancher formellement sur la superiorite du dosage urinaire par rapport au dosage plasmatique pour le depistage des atteintes renales aigues. Il n’en reste pas moins que sur le plan analytique, les techniques de dosage du NGAL urinaire sont actuellement plus fiables que celles du dosage plasmatique. La performance diagnostique de NGAL dans un contexte d’IRA est maximale en chirurgie cardiaque pediatrique. Les resultats, chez l’adulte en postoperatoire de chirurgie cardiaque et dans d’autres situations (reanimation, urgences, transplantation), sont moins convaincants. Par ailleurs, il n’est actuellement pas possible d’extrapoler des etudes cliniques une valeur seuil discriminante unique de NGAL, aussi bien dans les urines que dans le plasma. D’autres etudes sont necessaires pour valider definitivement NGAL comme biomarqueur de l’atteinte renale aigue et en preciser les conditions d’utilisation en pratique clinique. [less ▲]

Detailed reference viewed: 72 (8 ULg)
Full Text
Peer Reviewed
See detailLe dosage urinaire et plasmatique du NGAL: étude analytique et implications pratiques pour le clinicien
Cavalier, Etienne ULg; Rozet, Eric ULg; Bekaert, Anne-Catherine ULg et al

in Néphrologie & Thérapeutique (2010, September), 6(5), 350

Detailed reference viewed: 65 (3 ULg)
Full Text
Peer Reviewed
See detailUrinary NGAL: Use of absolute value or ratio to creatinine?
Cavalier, Etienne ULg; Bekaert, Anne-Catherine ULg; Legrand, Delphine ULg et al

in Acta Clinica Belgica (2010), 65-3

Introduction: Neutrophil gelatinase-associated lipocalin (NGAL) has emerged as a promising marker for the detection of acute kidney injury. This marker has been proposed for urinary measurement. However ... [more ▼]

Introduction: Neutrophil gelatinase-associated lipocalin (NGAL) has emerged as a promising marker for the detection of acute kidney injury. This marker has been proposed for urinary measurement. However, in the literature, authors indistinctly use "absolute" value or NGAL to creatinine ratio. Up to now, there are no strong arguments favouring for one. This question is of importance as this marker is sensed to be used only on urine random samples. To find an answer to this very practical matter, one approach could be to compare biological CV(intra-individual variation) of the "absolute" and ratio results. [less ▲]

Detailed reference viewed: 249 (0 ULg)
Full Text
Peer Reviewed
See detailQuelle place pour une double ou triple inhibition du systeme renine-angiotensine-aldosterone ?
Legrand, Delphine ULg; Krzesinski, Jean-Marie ULg; Scheen, André ULg

in Revue Médicale Suisse (2008), 4(168), 1792-7

The blockade of the renin-angiotensin-aldosterone system (RAAS) is helpful in the management of arterial hypertension, congestive heart failure, post-myocardial infarction and diabetic nephropathy. Such ... [more ▼]

The blockade of the renin-angiotensin-aldosterone system (RAAS) is helpful in the management of arterial hypertension, congestive heart failure, post-myocardial infarction and diabetic nephropathy. Such blockade can be obtained with an angiotensin converting enzyme inhibitor, a specific antagonist of angiotensin II AT1 receptors, an aldosterone receptor antagonist and/or a direct inhibitor of renin such as aliskiren. Various studies have demonstrated that a dual or even triple RAAS inhibition may offer a better cardiorenal protection, in refractory congestive heart failure and in nephropathy with proteinuria. However, in the ONTARGET study, the dual inhibition with ramipril plus telmisartan did not provide any additional benefit compared to ramipril alone in high-risk cardiovascular patients, but showed a worse tolerance profile. [less ▲]

Detailed reference viewed: 56 (9 ULg)
Full Text
Peer Reviewed
See detailLa consommation reguliere de cafe reduirait le risque de diabete de type 2.
Legrand, Delphine ULg; Scheen, André ULg

in Revue Médicale de Liège (2007), 62(9), 554-9

The prevention of type 2 diabetes has become a major public health objective. Cross-sectional studies have shown a lower prevalence of type 2 diabetes among coffee drinkers. The present article ... [more ▼]

The prevention of type 2 diabetes has become a major public health objective. Cross-sectional studies have shown a lower prevalence of type 2 diabetes among coffee drinkers. The present article synthesizes results of recent prospective studies, which assessed the relative risk of developing type 2 diabetes according to coffee consumption. Most studies confirm a protective effect against type 2 diabetes, with some dose-response in function of the degree of daily coffee consumption. The observed effect is rather impressive (relative risk reduced to almost 0.70-0.40) and is present whatever the type of population. It appears equal, or event greater, with decaffeinated coffee as compared to regular coffee. These results suggest that the protective effect could not be attributed exclusively to caffeine, but rather that it should be explained by other components, most probably chlorogenic acid and/or various anti-oxidants. The precise mechanism explaining the protection of coffee against type 2 diabetes and its potential relevance in public health remain to be specified. [less ▲]

Detailed reference viewed: 102 (2 ULg)
Full Text
Peer Reviewed
See detailLa resistance a l'aspirine chez le patient diabetique: decouverte de laboratoire ou realite clinique?
Legrand, Delphine ULg; Scheen, André ULg

in Revue Médicale de Liège (2007), 62(10), 610-5

Aspirin is considered the gold standard antiplatelet therapy for primary and secondary prevention of cardiovascular (CV) disease. However, it appears less protective in diabetic patients than in the ... [more ▼]

Aspirin is considered the gold standard antiplatelet therapy for primary and secondary prevention of cardiovascular (CV) disease. However, it appears less protective in diabetic patients than in the general population. This difference is attributed to a higher level of aspirin resistance observed in these subjects when in vitro tests are performed. The frequency of this problem, its mechanistic aspects and its clinical relevance remain largely unknown. Our analysis of the literature confirms a higher proportion of platelets resistant to aspirin in diabetic than in control individuals. This observation deserves further research because it may be associated with an increased risk of CV events and worse prognosis. [less ▲]

Detailed reference viewed: 60 (2 ULg)
Full Text
Peer Reviewed
See detailPrevention cardiovasculaire par l'aspirine chez le patient diabetique: que nous apprend la medecine factuelle?
Legrand, Delphine ULg; Scheen, André ULg

in Revue Médicale Suisse (2006), 2(76), 1904-8

Diabetes mellitus markedly increases the risk of cardiovascular diseases, with an especially elevated relative risk among women. Aspirin prescription is mandatory in secondary prevention, even if the ... [more ▼]

Diabetes mellitus markedly increases the risk of cardiovascular diseases, with an especially elevated relative risk among women. Aspirin prescription is mandatory in secondary prevention, even if the protection by aspirin appears less efficacious in diabetic than in non-diabetic patients. In primary prevention, available data are paradoxically rather scarce, but also suggest a less effective prevention when diabetes is present. Aspirin remains the first antiplatelet agent in the diabetic population in all international guidelines of cardiovascular prevention although a higher daily dose may be proposed in this subgroup of patients (160-300 mg rather than 75-100 mg). [less ▲]

Detailed reference viewed: 76 (1 ULg)
Full Text
Peer Reviewed
See detailAspirin and clopidogrel resistance in patients with diabetes mellitus.
Scheen, André ULg; Legrand, Delphine ULg

in European Heart Journal (2006), 27(23), 29002900-1

Detailed reference viewed: 27 (2 ULg)
Full Text
Peer Reviewed
See detailL'aspirine en prevention primaire des maladies cardio-vasculaires chez le patient diabetique.
Legrand, Delphine ULg; Scheen, André ULg

in Revue Médicale de Liège (2006), 61(10), 682-90

Acetylsalicylic acid (aspirin) is widely used as antiplatelet therapy for the primary and secondary prevention of cardiovascular diseases. However, the effects appear to be different according to the ... [more ▼]

Acetylsalicylic acid (aspirin) is widely used as antiplatelet therapy for the primary and secondary prevention of cardiovascular diseases. However, the effects appear to be different according to the studied population, with a reduction of coronary events in men and, rather, a diminution of strokes in women. Diabetes mellitus markedly increases the risk of cardiovascular diseases, with an especially elevated relative risk among women. We present a detailed analysis of the literature about the efficacy of aspirin in the primary prevention of cardiovascular complications in the diabetic population. Limited available data suggest a lower protection in the diabetic than in the non-diabetic population. A greater aspirin resistance has been suggested in diabetic patents, which might lead to the use of a higher daily dosage of aspirin in diabetic than in non diabetic patients. Whatsoever, aspirin remains the first antiplatelet agent in the diabetic population in all international guidelines of cardiovascular prevention. [less ▲]

Detailed reference viewed: 300 (8 ULg)
Full Text
Peer Reviewed
See detailL'insulinotherapie par pompe externe a perfusion continue d'insuline.
Radermecker, Régis ULg; Hermans, M. P.; Legrand, Delphine ULg et al

in Revue Médicale de Liège (2005), 60(5-6), 329-34

Type I diabetes mellitus requires an exogenous supply of insulin that ideally mimics physiological insulin secretion. The treatment goal is to achieve normoglycaemia in order to prevent or delay chronic ... [more ▼]

Type I diabetes mellitus requires an exogenous supply of insulin that ideally mimics physiological insulin secretion. The treatment goal is to achieve normoglycaemia in order to prevent or delay chronic complications, while limiting the risk of hypoglycaemia. Numerous advances have been performed in the last 10 years, as far as nature of insulin formulations, home blood glucose monitoring devices and modes of insulin delivery. Among the latter, continuous subcutaneous insulin infusion (CSII) using portable pumps represents the most sophisticated treatment capable of best mimicking normal insulin secretion. Such treatment provides better glucose control and glucose stability as compared to conventional multiple injection insulin therapy. However, it is essential to respect well defined indications and to organize a structured management by a multidisciplinary team in order to get the best metabolic results. The present paper describes recommendations, advantages and limits as well as cost of CSII with portable pumps in type 1 diabetic patients. [less ▲]

Detailed reference viewed: 149 (6 ULg)